AstraZenecaSTU:ZEGA +1.30%87 Net Margin % is 20.15% as of Mar. 2026, which is 61% above its 10-year median of 12.51. GuruFocus rates STU:ZEGA with a GF Score™ of 87/100 and a GF Value™ of €74.34. The stock has 4 warning signs investors should review. Among 956 Drug Manufacturers companies, AstraZeneca ranks better than 83.05% on this metric.
Net margin is calculated as Net Income divided by its Revenue. AstraZeneca's Net Income for the
three
months ended in Mar. 2026 was €2,664 Mil. AstraZeneca's Revenue for the
three
months ended in Mar. 2026 was €13,224 Mil. Therefore, AstraZeneca's net margin for the quarter that ended in Mar. 2026 was 20.15%.
The historical rank and industry rank for AstraZeneca's Net Margin % or its related term are showing as below:
STU:ZEGA'
s Net Margin % Range Over the Past 10 Years
Min: 0.3 Med: 12.51 Max: 17.41
Current: 17.19
STU:ZEGA's Net Margin % is ranked better than 83.05% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs STU:ZEGA: 17.19
AstraZeneca (STU:ZEGA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
AstraZeneca Net Margin % Related Terms
AstraZeneca Net Margin % Historical Data
* Premium members only.
The historical data trend for AstraZeneca's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:ZEGA vs LLY, JNJ, ABBV: Net Margin % Comparison
For the Drug Manufacturers - General subindustry, AstraZeneca's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AstraZeneca Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Net Margin % distribution charts can be found below:
* The bar in red indicates where AstraZeneca's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AstraZeneca (STU:ZEGA) has a Net Margin % of 20.15% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on AstraZeneca and its competitors. This is 61% above median its historical median of 12.51. Over the past decade, AstraZeneca's Net Margin % has ranged from 0.30 to 17.41. According to the industry distribution chart, AstraZeneca ranks #162 out of 956 companies in the Drug Manufacturers industry, placing it in the top 16.9%.
Is AstraZeneca's Net Margin % too high?
AstraZeneca's current Net Margin % of 20.15% is 61% above median its 10-year median of 12.51. Over the past 10 years, this metric has ranged from a low of 0.30 to a high of 17.41. The Drug Manufacturers industry median Net Margin % is 5.56. AstraZeneca's value of 20.15% is 262.4% above this industry median. Based on the distribution chart, AstraZeneca ranks #162 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, AstraZeneca has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's Net Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, AstraZeneca ranks #162 out of 956 companies for Net Margin %. This places AstraZeneca in the top 17% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. AstraZeneca's value of 20.15% is 262.4% above this benchmark. Historically, AstraZeneca's own Net Margin % has ranged from 0.30 to 17.41 over the past decade. While the company's 10-year median is 12.51 vs. the industry median of 5.56, AstraZeneca has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AstraZeneca's current Net Margin % of 20.15% is 262.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on AstraZeneca and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AstraZeneca's current Net Margin % is 20.15%, which is 61% above median its own 10-year median of 12.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
AstraZeneca (STU:ZEGA) has a current Net Margin % of 20.15%. The stock's GF Value™ is €74.34, compared to a current price of €78.00 — trading 4.9% above its estimated fair value. The current Net Margin % is 20.15%, which is 61% above median its 10-year median of 12.51 and 262.4% above the Drug Manufacturers industry median of 5.56. AstraZeneca's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For AstraZeneca (STU:ZEGA), the current Net Margin % is 20.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AstraZeneca (STU:ZEGA) Overvalued in 2026?
Based on GuruFocus' analysis, AstraZeneca stock appears to be overvalued.
The current stock price of €78.00 is trading 4.9% above its estimated GF Value™ of €74.34.
Key valuation signals for STU:ZEGA:
Net Margin %: 20.15% (61% above median its 10-year median of 12.51)
GF Value™: €74.34 vs. price of €78.00 (4.9% above fair value)
Industry Position: 262.4% above the Drug Manufacturers median (#162 of 956)
No single metric tells the full story. See the STU:ZEGA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
87GF Score
Get the complete analysis for STU:ZEGA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:ZEGA has been successfully added to your 
